Clinical Report: Didymin Reduces Neuroinflammation and Maintains BBB Function
Overview
Didymin treatment improves neurological outcomes and reduces neuroinflammation following subarachnoid hemorrhage (SAH). It preserves blood-brain barrier (BBB) integrity and alleviates brain edema by downregulating matrix metalloproteinase 9 (MMP9) expression.
Background
Subarachnoid hemorrhage (SAH) is a severe type of stroke with high mortality and morbidity rates, primarily due to neuroinflammation and BBB disruption. The development of effective therapeutic strategies is critical to improve outcomes for SAH patients, as current interventions have limited efficacy. Didymin, a flavonoid glycoside, has shown promise in other models of central nervous system injury.
Data Highlights
Outcome
Effect of Didymin
Neurological function scores
Improved
Neuroinflammation
Reduced microglial activation and pro-inflammatory cytokines
BBB integrity
Preserved
Brain edema
Alleviated
MMP9 expression
Downregulated
Key Findings
Didymin improved neurological function scores in SAH rats.
It reduced neuroinflammation by inhibiting microglial activation and pro-inflammatory cytokines.
Didymin preserved blood-brain barrier integrity.
It alleviated brain edema by downregulating MMP9 expression.
In vitro, didymin promoted tight junction protein expression in human brain microvascular endothelial cells.
Clinical Implications
Further studies are warranted to explore the clinical applicability of didymin in human patients.
Conclusion
Didymin demonstrates neuroprotective effects in SAH by mitigating neuronal damage, suppressing neuroinflammation, and maintaining BBB integrity.
